Salt Lake City, UT, United States of America

Satish Kumar Nachaegari

This inventor holds 27 USPTO granted patents and 47 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in Oral Testosterone Therapy. Top assignees: Lipocine Inc., Spriaso LLC, Other. Active years: 2015-2025.

USPTO Granted Patents = 27 (Patent Applications = 47)

% Patents Active = 96.3

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 120(Granted Patents)

Location History:

Holladay, UT (US) (2016 - 2023)
Salt Lake City, UT (US) (2015 - 2024)

Company Filing History:

7 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

Areas of Expertise:

Oral Delivery

Androgen Prodrugs

Bioavailable Esters

Testosterone Therapy

Liver Disease

17-Hydroxyprogesterone

Oral Dosage Forms

Active Agents

Compositions

Solid State

Tridecanoate

Undecanoate

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12310978 - Composition and method for oral delivery of androgen prodrugs (2025-05-27),

2. 12303517 - Oral testosterone therapy (2025-05-20),

3. 12171770 - Bioavailable solid state (17-beta)-hydroxy-4-androsten-3-one esters (2024-12-24),

4. 12161651 - Oral testosterone therapy (2024-12-10),

5. 12150945 - Liver disease (2024-11-26),

6. 12097207 - Liver disease (2024-09-24),

7. 11992496 - Oral testosterone therapy (2024-05-28),

8. 11872235 - Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters (2024-01-16),

9. 11707467 - (17-ß)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use (2023-07-25),

10. 11672807 - Oral testosterone non-undecanoate therapy (2023-06-13),

11. 11590147 - 17-hydroxyprogesterone ester-containing oral compositions and related methods (2023-02-28),

12. 11559530 - Oral testosterone undecanoate therapy (2023-01-24),

13. 11471470 - 17-hydroxyprogesterone ester-containing oral compositions and related methods (2022-10-18),

14. 11298365 - Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters (2022-04-12),

15. 10881670 - Oral testosterone tridecanoate therapy (2021-01-05),

Title: Satish Kumar Nachaegari: A Pioneer in Inventing Bioavailable Pharmaceuticals

Introduction:

Satish Kumar Nachaegari, a dedicated inventor based in Salt Lake City, UT, is a true trailblazer in the realm of innovations. With a passion for pushing the boundaries of what is possible, Satish has become renowned for his relentless drive to create groundbreaking inventions that have the potential to revolutionize the pharmaceutical industry.

Latest Patents:

Among his impressive portfolio of 20 patents, Satish's latest inventions stand out for their potential impact on pharmaceutical science. His patents for "Bioavailable solid state (17-β)-Hydroxy-4-Androsten-3-one esters" and "(17-β)-3-oxoandrost-4-en-17YL tridecanoate compositions" showcase his expertise in developing novel pharmaceutical compositions that address critical health needs.

Career Highlights:

Satish Kumar Nachaegari has made significant contributions to the field of pharmaceuticals through his work at esteemed companies such as Lipocine Inc. His innovative spirit and dedication to scientific excellence have earned him a reputation as a visionary inventor who is constantly striving to improve the lives of individuals through cutting-edge pharmaceutical solutions.

Collaborations:

Throughout his career, Satish has collaborated with talented individuals such as Mahesh V Patel and Nachiappan Chidambaram. These partnerships have not only enhanced the innovative potential of his work but have also fostered a culture of collaboration and teamwork within the pharmaceutical research community.

Conclusion:

In conclusion, Satish Kumar Nachaegari's unwavering commitment to innovation and his pioneering spirit make him a standout figure in the world of inventions. His groundbreaking patents and successful collaborations underscore his profound impact on the pharmaceutical industry, positioning him as a leading inventor whose work continues to shape the future of healthcare.